Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gains from Sales and Divestitures (2016 - 2017)

Historic Gains from Sales and Divestitures for Ultragenyx Pharmaceutical (RARE) over the last 2 years, with Q4 2017 value amounting to $156021.0.

  • Ultragenyx Pharmaceutical's Gains from Sales and Divestitures rose 19847.34% to $156021.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $156021.0, marking a year-over-year increase of 19847.34%. This contributed to the annual value of $156021.0 for FY2017, which is 19847.34% up from last year.
  • As of Q4 2017, Ultragenyx Pharmaceutical's Gains from Sales and Divestitures stood at $156021.0, which was up 19847.34% from $52273.0 recorded in Q4 2016.
  • In the past 5 years, Ultragenyx Pharmaceutical's Gains from Sales and Divestitures registered a high of $156021.0 during Q4 2017, and its lowest value of $52273.0 during Q4 2016.